Document is current
Any future updates will be listed below
-
Authors
Makhzoum, Jean-Paul https://orcid.org/0000-0003-4523-8525
Avadisian, Miriam https://orcid.org/0009-0005-1177-7362
Liazoghli, Dalinda https://orcid.org/0009-0000-0319-6131
-
Funding
Funding for this research was provided by:
AbbVie Canada
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 5 December 2025
First Online: 24 December 2025
Declarations
:
: The research was conducted independently by the investigator at Hôpital du Sacré-Coeur de Montréal and the sponsor (AbbVie Corporation) had no role in the data collection. Jean-Paul Makhzoum reports consultancies, research grants, and speaker fees from the following: AbbVie, Otsuka, Amgen, Sanofi, Kabi Fresenius and AstraZeneca. He received a salary award from Fonds de Recherche du Québec and research funding from the Canadian Institutes of Health Research. Miriam Avadisian and Dalinda Liazoghli are employees of AbbVie Corporation.
: This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection began after the study received approval, from the institution’s Research Ethics Board (Certificate number is 2025–2884; REB: CIUSSS NIM—Hôpital du Sacré-Coeur de Montréal). This study was a retrospective cohort design using non-identifiable data from patients’ medical records and therefore patient consent was not required. All data were anonymized before analysis to ensure confidentiality. Only data specified in the protocol was submitted to AbbVie. Neither AbbVie nor any agents acting on behalf of AbbVie completed the case report forms.
